Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term tyrosine kinase. Found 26 abstracts

no pagination
Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Oct;127(1):70-4.   PMCID: PMC 3748717
Chandra HS, Heisterkamp NC, Hungerford A, Morrissette JJ, Nowell PC, Rowley JD, Testa JR. Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer Genetics. 2011 Apr;204(4):171-9.   PMCID: PMC3092778
Evans JD, Crown RA, Sohn JA, Seeger C. West Nile Virus Infection Induces Depletion of IFNAR1 Protein Levels. Viral Immunol. 2011 Aug;24(4):253-63.   PMCID: PMC3154464
Pisters PW, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Annals of Oncology. 2011 Nov;22(11):2523-9.   PMCID: not NIH funded
Sela M, Bogin Y, Beach D, Oellerich T, Lehne J, Smith-Garvin JE, Okumura M, Starosvetsky E, Kosoff R, Libman E, Koretzky G, Kambayashi T, Urlaub H, Wienands J, Chernoff J, Yablonski D. Sequential phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and mast cells. Embo Journal. 2011 Aug;30(15):3160-72.   PMCID: PMC3160187
Reichardt P, Blay JY, von Mehren M. Towards global consensus in the treatment of gastrointestinal stromal tumor. Expert Review of Anticancer Therapy. 2010 Feb;10(2):221-32.   PMCID: PMC347555
Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G(1) Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2. Journal of Clinical Oncology. 2010 Feb;28(5):780-7.   PMCID: PMC2834394
Xia MC, Qi QA, Jin Y, Wiest DL, August A, Xiong N. Differential Roles of IL-2-Inducible T Cell Kinase-Mediated TCR Signals in Tissue-Specific Localization and Maintenance of Skin Intraepithelial T Cells. Journal of Immunology. 2010 Jun;184(12):6807-14.   PMCID: PMC2941197
Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P. A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors. Clinical Cancer Research. 2009 Sep;15(18):5910-6.   PMCID: PMC2861356
Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabro F, Cheng ST, Trudel GC, Paliwal P, Sternberg CN. Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 2009 Dec;15(23):7421-8.   PMCID: PMC 3394097
Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. JOURNAL OF CLINICAL ONCOLOGY. 2006 Oct;24(29):4764-74.
Ronty M, Taivainen A, Moza M, Kruh GD, Ehler E, Carpen O. Involvement of palladin and alpha-actinin in targeting of the Abl/Arg kinase adaptor ArgBP2 to the actin cytoskeleton. Experimental Cell Research. 2005 Oct 15;310(1):88-98.
von Mehren M. Targeted therapy with imatinib: Hits and misses?. Journal of Clinical Oncology. 2005 Jan;23(1):8-10.
Wen LJ, Brill-Dashoff J, Shinton SA, Asano M, Hardy RR, Hayakawa K. Evidence of marginal-zone B cell-positive selection in spleen. Immunity. 2005 Sep;23(3):297-308.
Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S, Demetri GD, Joensuu H. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 2004 Apr;103(8):2929-35.
Haks MC, Pepin E, van den Brakel JH, Smeele SA, Belkowski SM, Kessels H, Krimpenfort P, Kruisbeek AM. Contributions of the T cell receptor-associated CD3 gamma-ITAM to thymocyte selection. Journal of Experimental Medicine. 2002 Jul;196(1):1-13.
Iijima Y, Okuda K, Tojo A, Tri NK, Setoyama M, Sakaki Y, Asano S, Tokunaga K, Kruh GD, Sato Y. Transformation of Ba/F3 cells and rat-1 cells by ETV6/ARG. Oncogene. 2002 Jun 27;21(28):4374-83.
Chumley MJ, Dal Porto JM, Kawaguchi S, Cambier JC, Nemazee D, Hardy RR. A V(H)11V(kappa)9B cell antigen receptor drives generation of CD5(+) B cells both in vivo and in vitro. Journal of Immunology. 2000 May;164(9):4586-93.
Lozano F, Simarro M, Calvo J, Vila JM, Padilla O, Bowen MA, Campbell KS. CD5 signal transduction: Positive or negative modulation of antigen receptor signaling. Critical reviews in immunology. 2000 Jan;20(4):347-58.
Campbell KS, Colonna M. DAP12: a key accessory protein for relaying signals by Natural Killer cell receptors. International Journal of Biochemistry & Cell Biology. 1999 Jun;31(6):631-6.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term tyrosine kinase

tyrosine kinase expression mesylate gene signal transduction acquired-resistance imatinib mesylate antigen receptor chronic myeloid-leukemia inhibitor positive selection gastrointestinal stromal tumors c-kit inhibition dose imatinib sunitinib kit mutations alpha-beta myeloid-leukemia b-1 cells negative selection translocation lymphocytes-b imatinib acute lymphoblastic-leukemia sh2 domains dengue virus stromal tumor langerhans cells substrate docking tyk2 mice clinical-response endoplasmic-reticulum stress activation bms-354825 biology imatinib-resistant phospholipase sh2 stem-cell factor encodes missense mutation membrane glycoprotein marrow interferon-alpha receptor ly-49d chain signaling motifs monoclonal- guidelines mitoxantrone plus prednisone 2008 orge s-j clin oncol-v26 receptor mice lacking registry residual disease receptor-induced activation antitumor-activity phase-ii raf kinase 7 days CD6 human Network growth trials etv6-ntrk3 gene fusion protein-kinase-c signal integration ZAP-70 bone- transgenic mice phosphatidylinositol 3-kinase thymocyte development protein tyrosine phosphorylation responses fate ABL BCR-translocation-imatinib-targeted therapies girdle muscular-dystrophy sarcomeric protein receptor-gamma-delta dose-escalation Syk C-gamma colorectal-cancer leukemia ETV6 family TCR signaling oligomerization SLP-76 ige production European Society of Medical Oncology region gene-expression recognize phosphatidyl choline Oncology zoledronic acid encephalitis KIT chronic myelomonocytic leukemia 2003 silva cm-pathol oncol res-v9-p13 wild-type adaptor proteins metastatic nk cells mouse lymphocytes-t amn107 cancer-patients 2007 orge s-j clin oncol-v25 activating receptors tec family kinases phase-i serum chronic myelogenous-leukemia zeta-chain cd4(+)cd8(+) thymocytes National Comprehensive Cancer src homology-2 domain abl phase-ii trial lymphocyte development signal-transduction pathway cell days on z-disc cell lung-cancer kinase inhibitor complex mouse model resistance fc-epsilon-ri CD5 2008 matteo d-p am soc clin oncol-v26 therapy chronic myelocytic-leukemia solid src family kinases thy-1 glycoprotein ITAM multiplicity T cell activation ArgBP2 palladin-cardiomyocyte-z-disc-cytoskeleton bone metastases tcr caveolin-1 ITAM survival gastrointestinal ARG tumors patient
Last updated on Friday, August 07, 2020